L'allaitement est possible en cas de traitement maternel par l'enoxaparine

Guillonneau, M; Crepy, A. De; Aufrant, C; Hurtaud‐Roux, Marie‐Françoise; Jacqz-Aigrain, Évelyne

doi:10.1016/0929-693x(96)86421-9

Cited by 8 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12 Furthermore, neither UFH nor LMWH are orally bioavailable and breastfeeding is considered safe. 13 The mechanism for both UFH and LMWH is potentiation of the natural anticoagulant antithrombin. Because of fewer side effects and a longer half-life, LMWHs are preferred to UFH.…”

Section: Traditional Anticoagulantsmentioning

confidence: 99%

See 1 more Smart Citation

Novel Antithrombotic Agents in Pregnancy Anticoagulants and Antiplatelet Agents

James

Sugrue

Federspiel

2022

Clinical Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

Increasing rates of thromboembolic complications have required increasing use of anticoagulant and antiplatelet agents during and after pregnancy. Furthermore, thromboembolism is both a cause and a complication of severe maternal morbidity requiring intensive care. As a consequence, almost all patients admitted to intensive care units receive an anticoagulant or an antiplatelet agent (or both) for either treatment or prevention of thromboembolism. In this review, we summarize commonly used anticoagulants and antiplatelet agents and outline the potential role of newly developed (novel) antithrombotic agents for pregnant and postpartum patients.

show abstract

Section: Traditional Anticoagulantsmentioning

confidence: 99%

“…Neither UFH nor LMWH crosses the placenta,12 and both are considered safe for mother and fetus 12. Furthermore, neither UFH nor LMWH are orally bioavailable and breastfeeding is considered safe 13. The mechanism for both UFH and LMWH is potentiation of the natural anticoagulant antithrombin.…”

Section: Traditional Anticoagulantsmentioning

confidence: 99%